21 completed, 1 unknown. 22 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 21, Unknown 1 |
Follow Fluvoxamine: new trials by email Literature Review of Fluvoxamine trials Research Report on Fluvoxamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers KP-001, Rosuvastatin calcium10mg, Caffeine citrate - Healty Volunteers | Phase 1 | Completed | Kaken Pharmaceutical | 38 | 2025-02-13 | 2025-09-12 |
| Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects Fluvoxamine, Itraconazole, Paroxetine - Drug Drug Interaction | Phase 1 | Completed | Asceneuron S.A. | 50 | 2024-02-22 | 2024-12-18 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects Savolitinib, Fluvoxamine - Healthy Male Subjects | Phase 1 | Completed | AstraZeneca | 16 | 2023-06-02 | 2023-08-29 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant Miricorilant, Fluvoxamine - Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Corcept Therapeutics | 26 | 2023-01-24 | 2023-03-22 |
| A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers | Phase 1 | Completed | MODAG GmbH | 54 | 2022-09-12 | 2023-03-23 |
| Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status Voriconazole 200mg, FluvoxaMINE 50 Mg Oral Tablet, Omeprazole 10 MG Oral Tablet - Healthy | Phase 1 | Unknown | University Hospital, Geneva | 45 | 2022-04-01 | 2022-11-03 |
| Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 Caffeine, ABX464, Fluvoxamine - Healthy | Phase 1 | Completed | Abivax S.A. | 59 | 2020-12-17 | 2026-11-09 |
| A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers AZD4635, Fluvoxamine - Healthy Volunteer/DDI Study | Phase 1 | Completed | AstraZeneca | 28 | 2020-07-21 | 2021-01-06 |
| Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165 BMS-986165, Fluvoxamine - Healthy | Phase 1 | Completed | Bristol-Myers Squibb | 16 | 2019-05-01 | 2021-11-17 |
| Drug-Drug Interaction (DDI) Study for TD-9855 TD-9855, Fluvoxamine, Itraconazole - Drug Drug Interaction (DDI) | Phase 1 | Completed | Theravance Biopharma | 41 | 2018-02-28 | 2021-01-14 |
| Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122 CC-122, Itraconazole, Fluvoxamine - Healthy Volunteer | Phase 1 | Completed | Celgene | 81 | 2017-11-09 | 2019-01-16 |
| Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 Fluvoxamine, BI 409306 - Powder for oral solution (PfOS), BI 409306 - film coated tablet - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 18 | 2016-08-25 | 2024-08-21 |
| Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. dovitinib (TKI258), fluvoxamine - Advanced Solid Tumors, Excluding Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 45 | 2013-05-01 | 2020-12-21 |
| A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects Pomalidomide, Ketoconazole, Fluvoxamine - Pharmacology, Clinical, Healthy | Phase 1 | Completed | Celgene | 32 | 2012-09-01 | 2019-11-12 |
| A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers Fluvoxamine, RO4917523 - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 16 | 2012-07-01 | 2016-11-02 |
| Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine Tasimelteon, Fluvoxamine - Healthy Volunteers | Phase 1 | Completed | Vanda Pharmaceuticals | 24 | 2012-02-01 | 2014-02-17 |
| Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel fluvoxamine, citalopharm - Drug Interactions Between Clopidogrel and Serotonin Reuptake Inhibitors | Phase 1 | Completed | Hadassah Medical Organization | 15 | 2011-09-01 | 2013-01-29 |
| Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers FK949E, fluvoxamine - Healthy, Pharmacokinetics of Quetiapine | Phase 1 | Completed | Astellas Pharma Inc | 24 | 2011-07-01 | 2017-02-16 |
| Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel omeprazole, fluvoxamine, placebo - Drug Interaction of Clopidogrel | Phase 1 | Completed | Hadassah Medical Organization | 15 | 2011-01-01 | 2015-08-19 |
| Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes fluvoxamine, Digoxin - Depression | Phase 1 | Completed | Karolinska Institutet | 14 | 2008-08-01 | 2015-09-01 |
Showing 20 of 22. Sign in to see all of them.
Alzheimer Disease (1) · Depression (1) · Multiple System Atrophy (1) · Neurodegenerative Diseases (1) · Non-alcoholic Fatty Liver Disease (1) · Parkinson Disease (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Smoking (1) · Tauopathies (1)
AstraZeneca (2) · Celgene (2) · Hadassah Medical Organization (2) · Abivax S.A. (1) · Asceneuron S.A. (1) · Astellas Pharma Inc (1) · Avigen (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Corcept Therapeutics (1) · Heidelberg University (1) · Hoffmann-La Roche (1) · Kaken Pharmaceutical (1) · Karolinska Institutet (1) · MODAG GmbH (1)
United States (10) · United Kingdom (3) · Germany (2) · Netherlands (2) · Switzerland (2) · Denmark (1) · France (1) · Israel (1) · Japan (1) · Sweden (1)
Caroline Samer, Prof (1) · Joseph Custodio, PhD (1) · Leon Carayannopoulos, MD (1) · Maria Palmisano, MD (1) · Nand Singh, MD (1) · Pablo Forte Soto, Dr. (1) · Paul Gineste (1) · Rolf Pokorny, MD (1)
2016 (1)